Brought to you by 
Actelion partners orexin antagonist for insomnia with GSK
18 Feb 2011
Executive Summary
Swiss biotech Actelion has licensed GlaxoSmithKline exclusive worldwide rights (outside Japan) to co-develop and co-promote its Phase III almorexant for primary insomnia plus additional indications. Almorexant, an orexin receptor antagonist, is an oral agent that can penetrate the blood-brain barrier.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actelion partners orexin antagonist for insomnia with GSK
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice